Rua Bioscience is trading at NZD 0.03, down 7.14%, on October 22; the clearest reported company-specific catalyst is a rights offer that raised approximately NZ$1.0 million against NZ$2.8 million sought. - The company said the proceeds do not fully meet its working-capital requirements. - The offer involved issuing new shares, and applications for remaining shortfall shares were to be allowed. - No separate October 22 company announcement explaining the decline was identified in the search results.